enGene (NasdaqCM:ENGN) Earnings Call Presentation

Non-Viral Genetic Medicine Corporate Presentation Disclaimers Cautionary Statement Regarding Forward-Looking Statements The lead program described herein is an investigational drug therapy that has not been subject to testing designed to demonstrate that the therapy is effective in humans or to provide a basis to predict in advance whether an adequate level of efficacy in humans will be demonstrated in further testing. Although deemed sufficient to permit further testing, the limited, early Phase 1 testing ...